Search research articles
Contact Us
Filters
Showing results (21-30 of 36) with videos related to
Page
of 4
Sort By:
Cancer Research
|
June 17, 2010
PIK3CA mutations in in situ and invasive breast carcinomas
Alexander Miron, Maria Varadi, Daniel Carrasco, et al.
Endocrinology
|
May 10, 2017
Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors
Wenya Linda Bi, Noah F Greenwald, Shakti H Ramkissoon, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 11, 2010
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC
Nasim Ahmadiyeh, Mark M Pomerantz, Chiara Grisanzio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2012
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia
Jennifer R Brown, Megan Hanna, Bethany Tesar, et al.
Genome Medicine
|
July 28, 2016
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
Andrea Garofalo, Lynette Sholl, Brendan Reardon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2016
Landscape of Genomic Alterations in Pituitary Adenomas
Wenya Linda Bi, Peleg Horowitz, Noah F Greenwald, et al.
Plos Genetics
|
July 26, 2012
Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway
Courtney A Lovejoy, Wendi Li, Steven Reisenweber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2014
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver
Catherine Emmanuel, Yoke-Eng Chiew, Joshy George, et al.
Nature Communications
|
December 14, 2023
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Paolo Tarantino, Hersh Gupta, Melissa E Hughes, et al.
Nature Communications
|
November 19, 2023
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Paolo Tarantino, Hersh Gupta, Melissa E Hughes, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 36) with videos related to
Sort By:
Page
of 4
Cancer Research
|
June 17, 2010
PIK3CA mutations in in situ and invasive breast carcinomas
Alexander Miron, Maria Varadi, Daniel Carrasco, et al.
Endocrinology
|
May 10, 2017
Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors
Wenya Linda Bi, Noah F Greenwald, Shakti H Ramkissoon, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 11, 2010
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC
Nasim Ahmadiyeh, Mark M Pomerantz, Chiara Grisanzio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2012
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia
Jennifer R Brown, Megan Hanna, Bethany Tesar, et al.
Genome Medicine
|
July 28, 2016
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
Andrea Garofalo, Lynette Sholl, Brendan Reardon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2016
Landscape of Genomic Alterations in Pituitary Adenomas
Wenya Linda Bi, Peleg Horowitz, Noah F Greenwald, et al.
Plos Genetics
|
July 26, 2012
Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway
Courtney A Lovejoy, Wendi Li, Steven Reisenweber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2014
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver
Catherine Emmanuel, Yoke-Eng Chiew, Joshy George, et al.
Nature Communications
|
December 14, 2023
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Paolo Tarantino, Hersh Gupta, Melissa E Hughes, et al.
Nature Communications
|
November 19, 2023
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Paolo Tarantino, Hersh Gupta, Melissa E Hughes, et al.
Page
of 4